Cargando…
Formulation Composition and Process Affect Counterion for CSP7 Peptide
Counterions commonly remain with peptides in salt form after peptide purification. In animal and human studies, acetate counterions are a safer and more acceptable choice for peptides than others (e.g., trifluoroacetate counterions). Various salt forms of caveolin-1 scaffolding domain (CSP7) affect...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835953/ https://www.ncbi.nlm.nih.gov/pubmed/31569515 http://dx.doi.org/10.3390/pharmaceutics11100498 |
_version_ | 1783466794851237888 |
---|---|
author | Sahakijpijarn, Sawittree Moon, Chaeho Koleng, John J. Williams, Robert O. |
author_facet | Sahakijpijarn, Sawittree Moon, Chaeho Koleng, John J. Williams, Robert O. |
author_sort | Sahakijpijarn, Sawittree |
collection | PubMed |
description | Counterions commonly remain with peptides in salt form after peptide purification. In animal and human studies, acetate counterions are a safer and more acceptable choice for peptides than others (e.g., trifluoroacetate counterions). Various salt forms of caveolin-1 scaffolding domain (CSP7) affect counterion volatilization. The development of lyophilized formulations containing volatile compounds is a challenge because these compounds sublimate away during the process. This work aims to investigate the effect of excipients and lyophilization parameters on the preservation of volatile compounds after lyophilization. The peak areas obtained from (1)H and (19)F NMR spectra were used to calculate the molar ratio of counterions to CSP7. We found that the pH modifier excipient had the greatest impact on the loss of counterions. By optimizing the molar ratio of bulking agent to CSP7, volatile compounds can be preserved after lyophilization. Higher chamber pressure during lyophilization can lower the sublimation rate of volatile compounds. Moreover, the loss of volatile compounds affects the stability of CSP7 due to the pH shift of reconstituted solutions, thereby causing peptide aggregation. The optimization of the formulation and processing helps preserve volatile compounds, thus minimizing the pH change of reconstituted solutions and maintaining the stability of peptide. |
format | Online Article Text |
id | pubmed-6835953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68359532019-11-25 Formulation Composition and Process Affect Counterion for CSP7 Peptide Sahakijpijarn, Sawittree Moon, Chaeho Koleng, John J. Williams, Robert O. Pharmaceutics Article Counterions commonly remain with peptides in salt form after peptide purification. In animal and human studies, acetate counterions are a safer and more acceptable choice for peptides than others (e.g., trifluoroacetate counterions). Various salt forms of caveolin-1 scaffolding domain (CSP7) affect counterion volatilization. The development of lyophilized formulations containing volatile compounds is a challenge because these compounds sublimate away during the process. This work aims to investigate the effect of excipients and lyophilization parameters on the preservation of volatile compounds after lyophilization. The peak areas obtained from (1)H and (19)F NMR spectra were used to calculate the molar ratio of counterions to CSP7. We found that the pH modifier excipient had the greatest impact on the loss of counterions. By optimizing the molar ratio of bulking agent to CSP7, volatile compounds can be preserved after lyophilization. Higher chamber pressure during lyophilization can lower the sublimation rate of volatile compounds. Moreover, the loss of volatile compounds affects the stability of CSP7 due to the pH shift of reconstituted solutions, thereby causing peptide aggregation. The optimization of the formulation and processing helps preserve volatile compounds, thus minimizing the pH change of reconstituted solutions and maintaining the stability of peptide. MDPI 2019-09-29 /pmc/articles/PMC6835953/ /pubmed/31569515 http://dx.doi.org/10.3390/pharmaceutics11100498 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sahakijpijarn, Sawittree Moon, Chaeho Koleng, John J. Williams, Robert O. Formulation Composition and Process Affect Counterion for CSP7 Peptide |
title | Formulation Composition and Process Affect Counterion for CSP7 Peptide |
title_full | Formulation Composition and Process Affect Counterion for CSP7 Peptide |
title_fullStr | Formulation Composition and Process Affect Counterion for CSP7 Peptide |
title_full_unstemmed | Formulation Composition and Process Affect Counterion for CSP7 Peptide |
title_short | Formulation Composition and Process Affect Counterion for CSP7 Peptide |
title_sort | formulation composition and process affect counterion for csp7 peptide |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835953/ https://www.ncbi.nlm.nih.gov/pubmed/31569515 http://dx.doi.org/10.3390/pharmaceutics11100498 |
work_keys_str_mv | AT sahakijpijarnsawittree formulationcompositionandprocessaffectcounterionforcsp7peptide AT moonchaeho formulationcompositionandprocessaffectcounterionforcsp7peptide AT kolengjohnj formulationcompositionandprocessaffectcounterionforcsp7peptide AT williamsroberto formulationcompositionandprocessaffectcounterionforcsp7peptide |